204 related articles for article (PubMed ID: 15026475)
1. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
Rustin GJ; Quinn M; Thigpen T; du Bois A; Pujade-Lauraine E; Jakobsen A; Eisenhauer E; Sagae S; Greven K; Vergote I; Cervantes A; Vermorken J
J Natl Cancer Inst; 2004 Mar; 96(6):487-8. PubMed ID: 15026475
[No Abstract] [Full Text] [Related]
2. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
Vergote I; Rustin GJ; Eisenhauer EA; Kristensen GB; Pujade-Lauraine E; Parmar MK; Friedlander M; Jakobsen A; Vermorken JB
J Natl Cancer Inst; 2000 Sep; 92(18):1534-5. PubMed ID: 10995813
[No Abstract] [Full Text] [Related]
3. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
Taylor PT; Haverstick D
J Natl Cancer Inst; 2005 Jan; 97(2):151; author reply 152. PubMed ID: 15657346
[No Abstract] [Full Text] [Related]
4. Re: Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.
Pisal N; Sindos M; Singer A
J Natl Cancer Inst; 2003 Feb; 95(4):331; author reply 331-2. PubMed ID: 12591991
[No Abstract] [Full Text] [Related]
5. Clinical practice. Screening for ovarian cancer.
Clarke-Pearson DL
N Engl J Med; 2009 Jul; 361(2):170-7. PubMed ID: 19587342
[No Abstract] [Full Text] [Related]
6. The clinical value of tumour markers in the management of ovarian cancer.
Rustin GJ
Ann Clin Biochem; 1996 Jul; 33 ( Pt 4)():284-9. PubMed ID: 8836386
[No Abstract] [Full Text] [Related]
7. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
[TBL] [Abstract][Full Text] [Related]
8. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
Rustin GJ; Quinnell TG; Johnson J; Clarke H; Nelstrop AE; Bollag W
Br J Cancer; 1996 Nov; 74(9):1479-81. PubMed ID: 8912548
[TBL] [Abstract][Full Text] [Related]
9. Increased CA 125 in tuberculous peritonitis.
Collazos J
Gut; 1995 Aug; 37(2):297. PubMed ID: 7557589
[No Abstract] [Full Text] [Related]
10. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M
Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214
[TBL] [Abstract][Full Text] [Related]
11. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.
Bast RC
Cancer; 2010 Jun; 116(12):2850-3. PubMed ID: 20564390
[No Abstract] [Full Text] [Related]
12. [Evaluation of serum sICAM-1 amd CA-125 in patients with ovarian tumors--preliminary report].
Rzymski P; Woźniak J; Opala T; Sajdak S; Drews K
Ginekol Pol; 2002 Nov; 73(11):1090-5. PubMed ID: 12722404
[TBL] [Abstract][Full Text] [Related]
13. Is CA 125 actually a tumor marker for ovarian cancer?
Collazos J
Acta Oncol; 1995; 34(2):268. PubMed ID: 7718270
[No Abstract] [Full Text] [Related]
14. Can rumors cause cancer?
Jones J
J Natl Cancer Inst; 2000 Sep; 92(18):1469-71. PubMed ID: 10995800
[No Abstract] [Full Text] [Related]
15. Risk of malignancy in sonographically confirmed ovarian tumors.
Miller RW; Ueland FR
Clin Obstet Gynecol; 2012 Mar; 55(1):52-64. PubMed ID: 22343229
[TBL] [Abstract][Full Text] [Related]
16. Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: a systematic review of international guidelines.
Funston G; Van Melle M; Baun ML; Jensen H; Helsper C; Emery J; Crosbie EJ; Thompson M; Hamilton W; Walter FM
BMC Cancer; 2019 Nov; 19(1):1028. PubMed ID: 31676000
[TBL] [Abstract][Full Text] [Related]
17. Listen for the "whispering disease".
Martin VR
Nurse Pract; 2000 Apr; 25(4):6-7. PubMed ID: 10790790
[No Abstract] [Full Text] [Related]
18. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.
Tamakoshi K; Kikkawa F; Hasegawa N; Ishikawa H; Mizuno K; Kawai M; Tomoda Y
Gynecol Obstet Invest; 1995; 39(2):125-9. PubMed ID: 7737582
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of soluble intracellular adhesion molecule-1 (sICAM-1) in women with benign ovarian tumors].
Rzymski P; Opala T; Woźniak J; Drews K; Sajdak S
Ginekol Pol; 2004 Oct; 75(10):785-92. PubMed ID: 15587910
[TBL] [Abstract][Full Text] [Related]
20. Tumour markers in ovarian cancer.
Kehoe S; Selman T
Hosp Med; 2001 Aug; 62(8):452-3. PubMed ID: 11530581
[No Abstract] [Full Text] [Related]
[Next] [New Search]
